H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Lisata Therapeutics (LSTA – Research Report) today and set a price target of $15.00. The company’s shares opened today at $3.16.
Pantginis covers the Healthcare sector, focusing on stocks such as Clene, Actinium Pharmaceuticals, and aTyr Pharma. According to TipRanks, Pantginis has an average return of -10.4% and a 32.46% success rate on recommended stocks.
Lisata Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $15.00.
See Insiders’ Hot Stocks on TipRanks >>
Based on Lisata Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $5.99 million. In comparison, last year the company had a GAAP net loss of $6.79 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caladrius Biosciences, Inc. is a biopharmaceutical company, which engages in developing products in cardiovascular and autoimmune disease that have the potential to restore the health of people with chronic illnesses. Its product pipeline includes CLBS12, CLBS14, and CLBS03. The company was founded on September 18, 1980 and is headquartered in Basking Ridge, NJ.
Read More on LSTA:
- Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
- Lisata Therapeutics reports Q4 EPS (76c), consensus ($1.01)
- Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
- Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time
